The CFO Who Priced Research Like Stock Options

In 1994, Harvard Business Review sat down with Judy Lewent, chief financial officer of Merck — then one of the most admired companies in the world — to ask how a pharmaceutical giant decides which billion-dollar, decade-long research programs to fund. Her answer was not the discounted-cash-flow orthodoxy taught in every MBA program. Merck, she explained, analyzed research investments using the mathematics of financial options.

The logic: a drug program is not one bet, it is a chain of them. A modest early investment buys the right — never the obligation — to fund the next phase if the science cooperates. Most programs die early and cheaply; the few that survive each gate justify the next, larger commitment. Valued as a single all-or-nothing NPV, almost every early-stage program looks like a loser. Valued as a sequence of options, the same pipeline is rationally fundable — because each stage caps the downside while keeping the upside alive.

You run staged bets too, whether or not you price them: the pilot before the rollout, the market test before the factory, the one hire before the team. The question is whether your decision process values that flexibility — or quietly bulldozes it with a now-or-never spreadsheet.

From Wall Street Math to Factory Floors

The term real options belongs to Stewart Myers of MIT, who coined it in his 1977 Journal of Financial Economics paper Determinants of Corporate Borrowing. His observation: a large part of a firm's value consists not of assets in place but of opportunities — the ability to make future investments on favorable terms. Those opportunities behave like call options on real assets, which meant the option-pricing revolution Fischer Black, Myron Scholes, and Robert Merton had just started in 1973 applied to more than stock certificates.

Avinash Dixit and Robert Pindyck's 1994 book Investment under Uncertainty turned the insight into a full framework, with a blunt message for the NPV faithful: when an investment is irreversible and can be delayed, the standard rule — invest whenever NPV is positive — is simply wrong. Committing today kills the option to commit tomorrow with better information, and that dead option is a real cost the spreadsheet never shows.

The Six Options Hiding in Your Roadmap

Real options come in a small standard taxonomy. Naming which one you actually hold is half the analysis:

Where NPV Thinking Quietly Destroys Value

None of this makes discounted cash flow wrong — it makes one of its silent assumptions wrong. A standard NPV treats the investment as now-or-never and management as passive: commit everything today, then watch the projected cash flows arrive or not. Under those assumptions, uncertainty can only hurt you, so higher variance means a bigger discount and a redder verdict.

Option thinking inverts the sign. If your downside is capped — you can stage, defer, or abandon — then variance is where the value lives: the bad futures cost you only the option premium, while the good futures pay in full. That is why a rigid NPV systematically under-values exactly the investments that matter most under uncertainty: research, platforms, new markets, anything staged. The number is not lying about the cash flows; it is lying about your freedom to respond to them — one more reason the metric is a premise in the investment argument, not the verdict on it.

Isn't This Just a License to Never Kill Anything?

The fair objection — because that is exactly how real options got abused. In the late-1990s boom, option language became the universal solvent for bad business cases: any money-losing venture could be defended as 'buying an option on the future.' If NPV says no but the option says maybe, the option always wins the meeting, and the discipline collapses into astrology with Greek letters.

The abuse inverts the theory. An option has value only because it has exercise conditions — a financial option specifies exactly when and at what price it converts or expires. A real option earns its valuation the same way: the expand option needs named triggers, and above all the abandonment option needs kill criteria — specific, observable conditions under which the project stops — decided while stopping is still cheap. Pre-committing those criteria is also the best defense against the loss-framed doubling-down that prospect theory predicts once a project starts bleeding. An option without an expiry and a strike is not an option; it is a hope with a budget line.

The Technique: Name the Option Before the Go/No-Go

Before your next significant commitment decision, add one agenda line: which option type is this, really? All-or-nothing, or stageable? Is there a defer option, and what does waiting cost versus reveal? If we proceed, what expand option does it open — and what abandonment option must we keep priced and honest?

Then force two entries into the alternatives list that now-or-never framing always deletes: 'commit later with more information' (the defer option, with its price named) and 'commit less, keep the gate' (the staging option, with its trigger named). Most go/no-go debates transform once those two are on the table as first-class alternatives instead of absences of courage.

What to Do With This

The Door You Keep Open

Merck's insight was never really about Black-Scholes. It was that a research pipeline — like a roadmap, like a strategy — is not one decision but a lattice of rights to decide later, and that those rights are worth real money precisely because the future is foggy. The mathematics priced the fog; the discipline was in respecting the gates.

Most organizations do the opposite twice over: they force staged bets through now-or-never spreadsheets, killing good options at birth — then let the surviving projects run gateless forever, because nobody wrote down when to stop. Value the flexibility. Then hold yourself to its terms.

Keeping the door open is a decision too. Decide it on purpose.